Reports Q1 revenue $51.72B, consensus $52.9M. “Vanda delivered strong commercial execution in the first quarter, highlighted by 26% growth in Fanapt sales, the groundbreaking U.S. launch of NEREUS with its pioneering direct-to-consumer platform at nereus.us, and the FDA approval of BYSANTI,” said CEO Mihael Polymeropoulos. “We believe that these achievements, combined with meaningful pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
- AnaptysBio price target lowered to $93 from $95 at Piper Sandler
- VNDA Earnings this Week: How Will it Perform?
- Vanda Pharmaceuticals announces commercial availability for Nereus
- Vanda Pharmaceuticals Adds Independent Director to Strengthen Board